40 Participants Needed

Ketotifen for Childhood Indigestion

(Ketotifen Trial)

CA
AB
Overseen ByAmber Bagherian, MS
Age: < 18
Sex: Any
Trial Phase: Phase 3
Sponsor: Children's Mercy Hospital Kansas City
Must be taking: Acid-reducing, Montelukast
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This trial tests ketotifen, a medication that stabilizes certain immune cells, in children aged 8-17 with functional dyspepsia who haven't responded to standard treatments. Ketotifen aims to reduce inflammation and pain by preventing these cells from releasing harmful substances.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop all current medications, but you cannot participate if you've used oral corticosteroids or oral cromolyn sodium in the past 6 months, or if you're taking certain medications like antipsychotics or opioids.

What data supports the effectiveness of the drug Ketotifen for childhood indigestion?

A study involving 42 allergic children with chronic abdominal complaints showed that Ketotifen had a favorable effect on the digestive tract, suggesting it may help with childhood indigestion.12345

Is Ketotifen safe for children?

Ketotifen has been studied in children for various conditions, including allergies and asthma, and is generally considered safe. Some children may experience drowsiness initially, but no serious side effects or laboratory abnormalities have been reported.14567

Research Team

CA

Craig A Friesen, MD

Principal Investigator

Children's Mercy Hospital Kansas City

Eligibility Criteria

This trial is for children aged 8-17 with functional dyspepsia and duodenal eosinophilia, who've had little to no relief from acid-reduction therapy and montelukast. They must have had a previous endoscopy showing specific levels of eosinophils. Kids can't join if they're on certain medications like opioids or have liver disease, diabetes, cancer, heart problems, respiratory or kidney diseases.

Inclusion Criteria

Evidence of written parental permission (consent) and subject assent
Negative pregnancy screening for females of childbearing potential
Previous endoscopy with biopsies demonstrating >20 eosinophils/high powered field on duodenal mucosal biopsies
See 3 more

Exclusion Criteria

I am a woman of childbearing age and do not use effective birth control.
Allergy to ketotifen or other products in capsule
I have not taken corticosteroids or cromolyn sodium in the last 4 weeks.
See 7 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants are randomly assigned to receive either ketotifen or placebo in a cross-over design, with each treatment lasting 28 days.

63 days
4 clinic visits, 3 phone interviews for responders; 3 clinic visits, 2 phone interviews for non-responders

Open-label extension

Initial ketotifen responders undergo an open-label twelve-week trial of ketotifen to assess sustainability.

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessments of heart rate, liver function, and quality of life.

12 weeks

Treatment Details

Interventions

  • Ketotifen
Trial Overview The study tests Ketotifen's effectiveness in treating indigestion linked to duodenal eosinophilia in kids who haven't improved with standard treatments. It compares Ketotifen against a placebo to see if it can replace more expensive therapies earlier in the treatment process.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: cross-over of KetotifenActive Control1 Intervention
Patients will begin the active ketotifen treatment first and cross over to placebo.
Group II: cross-over of PlaceboPlacebo Group1 Intervention
Patients will begin the placebo treatment first and cross over to the active ketotifen.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Children's Mercy Hospital Kansas City

Lead Sponsor

Trials
261
Recruited
941,000+

Findings from Research

Proton pump inhibitors (PPIs) like omeprazole and lansoprazole are more effective than histamine-2 receptor antagonists for treating gastroesophageal reflux disease (GERD) in children, with studies showing they effectively relieve symptoms and heal erosive esophagitis.
PPIs have a good safety profile in both adults and children, with minimal clinically significant drug interactions, and can be administered in various forms to accommodate children who have difficulty swallowing.
Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment.Gold, BD., Freston, JW.[2018]

References

Ketotifen in the treatment of changes of the upper part of digestive tract in allergic children. [2013]
Gastroesophageal reflux disease: could intervention in childhood reduce the risk of later complications? [2022]
Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. [2019]
Gastroesophageal reflux in children: pathogenesis, prevalence, diagnosis, and role of proton pump inhibitors in treatment. [2018]
Ketotifen in African children. [2013]
The role of ketotifen in children with recurrent bronchitis. [2017]
Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security